Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study
Background Mycophenolic acid (MPA) is recommended for the treatment of lupus nephritis (LN). However, the high pharmacokinetic (PK) variability of MPA contributes to its suboptimal efficacy and an increased incidence of adverse reactions. Rare data reported the impacts of genetic and clinical charac...
Saved in:
Main Authors: | Lu Zhang, Chen Ye, Yifan Zheng, Xiaoyun Jiang, Pan Chen, Kejing Tang, Baojing Liu, Lizhi Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-07-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/12/2/e001535.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A comparative study of pharmacokinetics of coated tablets of mycophenolic acid
by: A. L. Khokhlov, et al.
Published: (2016-11-01) -
Mycophenolate mofetil versus cyclophosphamide, in combination with prednisolone for lupus nephritis induction treatment: Findings from a prospective observational study
by: Rakhesh LR, et al.
Published: (2025-07-01) -
Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients After Renal Transplantation
by: Rath, Thomas, et al.
Published: (2012) -
USE OF MYCOPHENOLATE MOPHETYL IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: S.I. Valiyeva,, et al.
Published: (2006-03-01) -
Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01)